Abstract

Abstract Glioblastoma is a highly malignant tumour driven by a subset of self-renewing cells termed glioblastoma stem cells. This self-renewal phenotype is largely epigenetically driven, however, the exact epigenetic mechanisms underpinning it are poorly understood. We found that the histone variant macroH2A2 is repressed in a subset of glioblastoma tumours, and that this repression is associated with poorer survival. We interrogate the function of macroH2A2 using in vitro and in vivo patient-derived models. We show that macroH2A2 antagonizes self-renewal and expression of NPC and OPC-like markers, and rewires accessible chromatin by maintaining accessibility at a subset of enhancer elements. We identify small molecules that can upregulate macroH2A2 expression, and find that treatment with a small molecule reduces self-renewal, induces interferon sensitive genes, and a viral mimicry response, effects which are abolished by macroH2A2 knockdown. In summary, we identify macroH2A2 as a repressor of self-renewal in glioblastoma and suggest it may be a novel biomarker and potential marker of therapeutic susceptibility.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call